The Venture Codex

Participated · Equity · Feb 2025

BEKhealth, based in Research Triangle Park, NC, provides an AI-powered chart abstraction and patient-matching platform that extracts structured and unstructured data from electronic medical records (EMRs). The technology integrates EHR data to optimize population feasibility and rapidly identify clinically qualified participants for clinical research. Its platform supports organizations conducting clinical trials, observational research, and real-world evidence generation by improving protocol design and participant identification. The company announced customer growth in 2024 and now counts clients such as Avacare Clinical Research Network, Biopharma Informatics, Chemidox, Elixia Health, Javara, Om Research and others. BEKhealth raised $4M in funding and intends to use the proceeds to continue expanding its customer base and product offering. The company highlights its focus on expanding commercial adoption and enhancing its AI-driven capabilities to better serve research sponsors and sites. BEKHealth offers an AI-powered clinical research software platform that ingests and processes both structured and unstructured EMR data to drive feasibility assessments, site selection, precision patient matching, and care coordination. Its machine learning models combine more than 400 unique medical libraries and 70,000 research protocols with an interoperable clinical data model to power automated, daily identification of protocol-eligible patients. The platform is positioned to accelerate patient enrollment, cut timelines, and improve outcomes for sites and CROs while addressing cumbersome workflows and data access challenges. BEKHealth says its tools are increasingly in demand amid a more virtual healthcare environment and growing use of analytics in clinical research. The company is privately held, venture-backed, and based in Connecticut, and plans to use new funding to grow its team and expand availability and adoption of its platform.

Participated · Equity · Oct 2021

GoCheck builds GoCheck Kids, a digital vision screening platform used by pediatric teams to prevent vision impairment and blindness in children. The platform is FDA-registered and CE-certified. GoCheck serves 6,500 pediatric teams at hospitals, private practices, schools, and screening organizations across three continents. Led by CEO Kevon Saber, the company focuses on supporting pediatric teams in early detection of vision problems. GoCheck intends to use new funding to grow its team, expand the platform, and deepen customer partnerships. GoCheck Kids offers an iPhone photoscreening app that captures images of children’s eyes and uses proprietary algorithms to detect amblyopia risk factors, delivering immediate results to clinicians. The app is FDA-registered and CE-certified and is used by over 4,500 pediatricians. GoCheck Kids says it reduces screening costs by over 60% versus traditional hardware and bills insurers under CPT codes 99177 and 99174; pricing starts at $149 per month per phone. The company highlights endorsements from the American Academy of Pediatrics, the American Academy of Pediatric Ophthalmology and Strabismus, and the American Academy of Ophthalmology. Co-founder David Huang, MD, PhD, who co-invented OCT, leads innovation for the product. Future plans include adding AI capabilities using Apple’s CoreML and ARKit and accelerating electronic health record integrations. Gobiquity develops mobile vision screening applications, with its flagship GoCheck Kids combining photoscreening and digital visual acuity in a single app. GoCheck Kids, launched in 2015, is used by more than 2,000 U.S. pediatricians to identify amblyopia risk factors. The company has surpassed 100,000 screenings and now averages over 3,000 children screened per week, representing over 300% annual growth. Gobiquity recently released a new iPhone app for health care providers and plans to extend the product to caregivers and into adult primary care. Management says it is committed to evolving a validated, portable, and affordable mobile screening portfolio to address both children and adults. The company positions its tools as enabling early detection and prevention of vision impairment.

Participated · Equity · Aug 2018

410 Medical develops advanced resuscitation technologies centered on its lead product, the LifeFlow infuser, which received FDA clearance in 2016. LifeFlow is used by more than 500 hospitals and EMS agencies and has been used to treat nearly 80,000 patients experiencing conditions like sepsis and hemorrhagic shock. The company was founded in 2013 and is based in North Carolina. In July 2026 410 Medical raised $12 million in growth financing led by Orlando Health Ventures to scale commercial operations and accelerate LifeFlow adoption. The company is also investing in a next-generation LifeFlow device planned for launch in 2027. The financing was supported by a syndicate of hospital and healthcare investors, reflecting continued commercial momentum.